{"id":2335,"date":"2015-09-18T15:44:50","date_gmt":"2015-09-18T15:44:50","guid":{"rendered":"https:\/\/medicalcriteria.com\/web\/hepcm\/"},"modified":"2026-03-18T18:56:30","modified_gmt":"2026-03-18T18:56:30","slug":"hepcm","status":"publish","type":"post","link":"https:\/\/medicalcriteria.com\/web\/es\/hepcm\/","title":{"rendered":"Criterios Diagn\u00f3stico de Mieloma de C\u00e9lulas Plasm\u00e1ticas"},"content":{"rendered":"<div class=\"7ca9444b8380138fe077da07353677a4\" data-index=\"1\" style=\"float: none; margin:0px 0 0px 0; text-align:center;\">\n<script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\r\n<!-- MC 2019- Horizontal -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-0127150553352455\"\r\n     data-ad-slot=\"3806776041\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script>\n<\/div>\n<p>La definici\u00f3n de mieloma de c\u00e9lulas plasm\u00e1ticas se ha basado en la identificaci\u00f3n de las caracter\u00edsticas cl\u00ednicas y de laboratorio que predicen cuando una carga suficiente de c\u00e9lulas plasm\u00e1ticas se ha acumulado en el paciente que se beneficiar\u00e1 del tratamiento.<br \/>\n<!--more--><br \/>\n<b>Criterios diagn\u00f3stico de mieloma de c\u00e9lulas plasm\u00e1ticas<\/b><br \/>\n<b><\/b><\/p>\n<p><b>Mieloma de c\u00e9lulas plasm\u00e1ticas sintom\u00e1tico<\/b><\/p>\n<ul>\n<li>Prote\u00edna M en suero u orina*<\/li>\n<li>C\u00e9lulas plasm\u00e1ticas clonales en m\u00e9dula \u00f3sea (MO) o plasmocitoma\u2020<\/li>\n<li>Enfermedad por\u00a0cadenas pesadas que produce deterioro en \u00f3rganos o tejidos relacionados\u2021 (CRAB)<\/li>\n<\/ul>\n<p><b>Mieloma asintom\u00e1tico (indolente)<\/b><\/p>\n<ul>\n<li>Prote\u00edna M en el suero en niveles de mieloma (&gt; 30\u202fg\/l) y\/o &gt;\/= 10% de c\u00e9lulas plasm\u00e1ticas clonales en MO<\/li>\n<li>Ausencia de da\u00f1o en \u00f3rganos o tejidos de \u00f3rganos blanco o lesiones \u00f3seas [CRAB] o s\u00edntomas relacionados con mieloma<\/li>\n<\/ul>\n<p>CRAB indica hipercalcemia, insuficiencia renal, anemia, y lesiones \u00f3seas.<br \/>\n*No est\u00e1 incluido el nivel de prote\u00edna M en suero u orina. La prote\u00edna M en la mayor\u00eda de los casos es &gt;30\u202fg\/L de IgG o &gt; 25\u202fg\/L de IgA o &gt; 1\u202fg\/24\u202fh de cadenas livianas en orina, pero algunos pacientes con mieloma sintom\u00e1tico tienen niveles m\u00e1s bajos que estos.<br \/>\n\u2020Las c\u00e9lulas\u00a0plasm\u00e1ticas\u00a0monoclonales suelen superar el 10% de las c\u00e9lulas nucleadas en m\u00e9dula \u00f3sea, pero no hay niveles m\u00ednimos designados porque ~ 5% de los pacientes con mieloma sintom\u00e1tico tienen &lt;10%\u00a0c\u00e9lulas plasm\u00e1ticas en m\u00e9dula.<br \/>\n\u2021Los criterios m\u00e1s importantes para el mieloma sintom\u00e1tico son manifestaciones de da\u00f1o de \u00f3rgano blanco incluyendo anemia, hipercalcemia, lesiones \u00f3seas l\u00edticas, insuficiencia renal, hiperviscosidad, o infecciones recurrentes.<\/p>\n<p>&nbsp;<\/p>\n<p><b>Bibliograf\u00eda:<\/b><\/p>\n<ol>\n<li>Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011 May 12;117(19):5019-32.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/21300984\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.\u00a0Br J Haematol. 2003 Jun;121(5):749-57.\u00a0<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/12780789\/\" target=\"_blank\" rel=\"noopener noreferrer\">[Medline]<\/a><\/li>\n<li>Avet-Loiseau H, Davies FE, Samur MK, Corre J, D&#8217;Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Pr\u00f3sper F, Munshi NC. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025 Aug 20;43(24):2739-2751. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40489728\/\" target=\"_blank\" rel=\"noopener\">[Medline]<\/a><\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<p>Creado Sep 29, 2015.<br \/>\nActualizado Mar 18, 2026.<\/p>\n\n<div style=\"font-size: 0px; height: 0px; line-height: 0px; margin: 0; padding: 0; clear: both;\"><\/div>","protected":false},"excerpt":{"rendered":"<p>La definici\u00f3n de mieloma de c\u00e9lulas plasm\u00e1ticas se ha basado en la identificaci\u00f3n de las caracter\u00edsticas cl\u00ednicas y de laboratorio que predicen cuando una carga suficiente de c\u00e9lulas plasm\u00e1ticas se ha acumulado en el paciente que se beneficiar\u00e1 del tratamiento.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"no","_lmt_disable":"no","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[171],"tags":[757,756,16,15,14,13,755,754,753,752,758],"class_list":["post-2335","post","type-post","status-publish","format-standard","hentry","category-hematology","tag-cell","tag-celulas","tag-criteria","tag-criterios","tag-diagnostic","tag-diagnostico","tag-mieloma","tag-myeloma","tag-pcm","tag-plasma","tag-plasmaticas"],"modified_by":"Guillermo Firman","_links":{"self":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/comments?post=2335"}],"version-history":[{"count":4,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2335\/revisions"}],"predecessor-version":[{"id":10712,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/posts\/2335\/revisions\/10712"}],"wp:attachment":[{"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/media?parent=2335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/categories?post=2335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalcriteria.com\/web\/es\/wp-json\/wp\/v2\/tags?post=2335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}